The Leeds Teaching Hospitals NHS Trust


As one of the UK’s largest liver centres we are active in research.

Hepatology & Liver Transplantation Trials

Open to recruitment:

  • Organ Care System (OCS™) Liver ‘REVIVE’ Trial
  • UK PBC genetics study
  • UK PSC genetics study
  • HCV Research UK
  • UK-AIH (United Kingdom Autoimmune Hepatitis Cohort)
  • AbbVie - A single arm, open label, multicentre study to evaluate the safety and efficacy of ABT-493/ABT-530 in adult post liver or post renal transplant recipients with chronic hepatitis c virus genotype 1-6 (MAGELLAN-2)
  • EON
  • Steroid HCC
  • NUT-3

Open trials in follow-up:

  • An Open-Label, Multicenter Study to EvaluateLong-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
  • STOP-HCV cirrhosis study
  • LIFT Liver Immunosuppression-free trial
  • Nucleos(t)ide withdrawal in hepatitis B virus infection (NUC-B)

Previous trials now closed:

  • WAFT-C Warfarin Anticoagulation for liver fibrosis in patients transplanted for HCV
  • LEAN Liraglutides Action and efficacy in NASH
  • ELUCIDATE ELF to Uncover Cirrhosis as an indication for Diagnosis and action for treatable events
  • ELUCIDATE patients experience
  • GILEAD A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection
  • ATTAIN(Retreatment of null and partial responders with TMC435) A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy
  • DILIGEN Pharmacogenetics of drug induced liver injury
  • STOPAH. Steriods or Pentoxifylline for Alcoholic Hepatitis
  • Drug Utilization of DAAs and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Patients
  • Hepatitis C Rimantadine and Antiviral Combination Therapy – “HepRiACT” trial
  • UK-PBC Nested Cohort Study
  • Albumin to prevent infection in chronic liver failure (ATTIRE)
  • Phase 2 EDP-305 in patients with primary biliary cholangitis
  • PROSPER (Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients’ Experience of Rifaximin)
  • A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure
  • GILEAD - A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have received a Liver Transplant
  • TACE-2 Research trial evaluating sorafenib in combination with chemoembolization in patients with unresectable advanced Hepatocellular Carcinoma